{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:11:25Z","timestamp":1785247885669,"version":"3.55.0"},"reference-count":66,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Cultivating Young Talents of Zhejiang Chinese Medical University","award":["701100E029"],"award-info":[{"award-number":["701100E029"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ovarian cancer (OC) remains one of the most lethal gynecologic malignancies. Olaparib plus cediranib has shown therapeutic promise, but its efficacy and safety remain inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of olaparib plus cediranib compared with other treatments in the maintenance treatment of OC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and Methods<\/jats:title>\n                    <jats:p>Following PRISMA 2020, we searched PubMed, Web of Science, Scopus, CNKI, and Wanfang databases up to June 2026 for RCTs comparing the combination with control treatments. Risk of bias was assessed using RoB 2, and certainty of evidence was evaluated using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine RCTs with 1,683 patients were included. Across all comparators, the combination significantly prolonged progression-free survival (PFS) (overall HR = 0.78; 95% CI: 0.68\u20130.89;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). No significant benefit was observed in overall survival (OS) or overall objective response rate (ORR), demonstrated improved ORR compared with olaparib or cediranib monotherapy, but not compared with chemotherapy or olaparib plus durvalumab. The combination significantly improved PFS in the BRCA wild-type\/unknown subgroup (HR = 0.79, 95% CI: 0.65\u20130.97;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.020), whereas no statistically significant benefit was observed in the BRCA-mutated subgroup (HR = 0.77, 95% CI: 0.54\u20131.11;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.160). There was no statistical evidence that BRCA mutation status modified the treatment effect. It increased risks of gastrointestinal, vascular, and fatigue-related adverse events, while reducing some hematologic toxicities. Evidence certainty ranged from very-low to moderate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Olaparib plus cediranib may prolong PFS in OC, and the benefit may limit in BRCA-mutated populations, but no clear OS benefit was observed and toxicity was increased. Because trials were judged to be at high risk of bias and the certainty of evidence ranged from very-low to moderate, these findings should be interpreted cautiously and considered hypothesis-generating.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15330338261472998","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:56:25Z","timestamp":1784980585000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Olaparib Combined With Cediranib in the Treatment of Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8799-0366","authenticated-orcid":false,"given":"Shuyan","family":"Li","sequence":"first","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9419-8254","authenticated-orcid":false,"given":"An","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"},{"name":"University of Helsinki"},{"name":"Helsinki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21559"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02486-4"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1183285"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2018-000125"},{"key":"e_1_3_8_6_2","article-title":"Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer (Version 4.2026)","author":"National Comprehensive Cancer Network","unstructured":"National Comprehensive Cancer Network. Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer (Version 4.2026). National Comprehensive Cancer Network (NCCN). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf. Accessed June 16, 2026.","journal-title":"National Comprehensive Cancer Network (NCCN)"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2016.12.005"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020470"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.01.059"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001640"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139026"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.61"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00237"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03003-9"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2283"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70228-1"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2022.2151883"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01167-8"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.23.2777"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13989"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(22)01296-3"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.73"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201019666180713102656"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav4508"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.01.015"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00683"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70391-2"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz018"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02011"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02567-6"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34696"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00123"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3877"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02589"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.106032"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1505889"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2373680"},{"key":"e_1_3_8_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.15885"},{"key":"e_1_3_8_44_2","volume-title":"The GRADE handbook","author":"Sch\u00fcnemann H","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, et al. The GRADE handbook. GRADEpro GDT. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html. Accessed September 11, 2025."},{"key":"e_1_3_8_45_2","volume-title":"Review Manager (RevMan) (Version 5.4.1)","author":"The Cochrane Collaboration","unstructured":"The Cochrane Collaboration. Review Manager (RevMan) (Version 5.4.1). https:\/\/revman.cochrane.org\/info. Accessed September 11, 2025."},{"key":"e_1_3_8_46_2","doi-asserted-by":"publisher","DOI":"10.1515\/ijb-2022-0070"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_3_8_48_2","volume-title":"Stata Statistical Software: Release 15.0","author":"StataCorp LLC","unstructured":"StataCorp LLC. Stata Statistical Software: Release 15.0. https:\/\/www.stata.com\/stata15\/. Accessed September 11, 2025."},{"key":"e_1_3_8_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_3_8_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341x.2000.00455.x"},{"key":"e_1_3_8_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35151"},{"key":"e_1_3_8_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02947"},{"key":"e_1_3_8_53_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1713163"},{"key":"e_1_3_8_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13758"},{"key":"e_1_3_8_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212"},{"key":"e_1_3_8_56_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M513033200"},{"key":"e_1_3_8_57_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01196-x"},{"key":"e_1_3_8_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.53"},{"key":"e_1_3_8_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040"},{"key":"e_1_3_8_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753"},{"key":"e_1_3_8_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"key":"e_1_3_8_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_3_8_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5809"},{"key":"e_1_3_8_64_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1156857"},{"key":"e_1_3_8_65_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207399"},{"key":"e_1_3_8_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds289"},{"key":"e_1_3_8_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp369"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338261472998","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338261472998","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338261472998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:49:14Z","timestamp":1785246554000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338261472998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":66,"alternative-id":["10.1177\/15330338261472998"],"URL":"https:\/\/doi.org\/10.1177\/15330338261472998","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338261472998\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261472998\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261472998\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261472998\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261472998\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261472998\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261472998\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261472998\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"15330338261472998"}}